CHRS Earnings Coherus Oncology, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–47 of 47
| Q2 2026 | 2026-06-30 | -0.13 | 2026-08-05 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.28 | 2026-05-11 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -3.40 | 2026-03-09 | 10-K |
| FY 2025 | 2025-12-31 | 1.43 | 2026-03-09 | 10-K |
| Q3 2025 | 2025-09-30 | -0.31 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | 2.57 | 2025-08-07 | 10-Q |
| Q1 2025 | 2025-03-31 | 2.57 | 2025-05-12 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -0.46 | 2025-03-17 | 10-K |
| FY 2024 | 2024-12-31 | 0.25 | 2025-03-17 | 10-K |
| Q3 2024 | 2024-09-30 | -0.09 | 2024-11-06 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.11 | 2024-08-08 | 10-Q |
| Q1 2024 | 2024-03-31 | 0.91 | 2024-05-09 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -0.67 | 2024-03-15 | 10-K |
| FY 2023 | 2023-12-31 | -2.53 | 2024-03-15 | 10-K |
| Q3 2023 | 2023-09-30 | -0.41 | 2023-11-06 | 10-Q |
| Q2 2023 | 2023-06-30 | -0.49 | 2023-08-02 | 10-Q |
| Q1 2023 | 2023-03-31 | -0.96 | 2023-05-08 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -0.76 | 2023-03-06 | 10-K |
| FY 2022 | 2022-12-31 | -3.76 | 2023-03-06 | 10-K |
| Q3 2022 | 2022-09-30 | -1.11 | 2022-11-08 | 10-Q |
| Q2 2022 | 2022-06-30 | -0.65 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | -1.24 | 2022-05-05 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | -0.55 | 2022-02-23 | 10-K |
| FY 2021 | 2021-12-31 | -3.81 | 2022-02-23 | 10-K |
| Q3 2021 | 2021-09-30 | -0.49 | 2021-11-08 | 10-Q |
| Q2 2021 | 2021-06-30 | -0.40 | 2021-08-05 | 10-Q |
| Q1 2021 | 2021-03-31 | -2.37 | 2021-05-06 | 10-Q |
| Q4 2020 (derived) | 2020-12-31 | 0.11 | 2021-02-25 | 10-K |
| FY 2020 | 2020-12-31 | 1.62 | 2021-02-25 | 10-K |
| Q3 2020 | 2020-09-30 | 0.33 | 2020-11-05 | 10-Q |
| Q2 2020 | 2020-06-30 | 0.70 | 2020-08-06 | 10-Q |
| Q1 2020 | 2020-03-31 | 0.48 | 2020-05-07 | 10-Q |
| Q4 2019 | 2019-12-31 | 0.53 | 2020-02-27 | 10-K |
| FY 2019 | 2019-12-31 | 1.23 | 2020-02-27 | 10-K |
| Q3 2019 | 2019-09-30 | 0.63 | 2019-11-08 | 10-Q |
| Q2 2019 | 2019-06-30 | 0.32 | 2019-08-05 | 10-Q |
| Q1 2019 | 2019-03-31 | -0.29 | — | — |
| FY 2018 | 2018-12-31 | -3.22 | — | — |
| Q3 2018 | 2018-09-30 | -0.87 | — | — |
| Q2 2018 | 2018-06-30 | -0.68 | — | — |
| FY 2017 | 2017-12-31 | -4.48 | — | — |
| Q3 2017 | 2017-09-30 | -1.09 | 2017-11-06 | 10-Q |
| Q4 2016 | 2016-12-31 | -1.71 | 2017-03-14 | 10-K |
| Q3 2016 | 2016-09-30 | 1.67 | 2016-11-09 | 10-Q |
| Q2 2017 | 2016-06-30 | -1.72 | — | — |
| Q1 2017 | 2016-03-31 | -1.67 | — | — |
| Q3 2015 | 2015-09-30 | -1.86 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.